Responses
Treating Idiopathic Pulmonary Fibrosis
P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states
Compose a Response to This Article
Other responses
No responses have been published for this article.